Log in to save to my catalogue

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antige...

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antige...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cc625c53f2e041649d56e52c14f79586

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

About this item

Full title

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

Publisher

Hoboken: John Wiley & Sons, Inc

Journal title

EJHaem, 2022-11, Vol.3 (4), p.1270-1276

Language

English

Formats

Publication information

Publisher

Hoboken: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti‐BCMA‐targeted chimeric antigen receptor‐T cell therapy. Here, we present data fro...

Alternative Titles

Full title

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_cc625c53f2e041649d56e52c14f79586

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cc625c53f2e041649d56e52c14f79586

Other Identifiers

ISSN

2688-6146

E-ISSN

2688-6146

DOI

10.1002/jha2.572

How to access this item